Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen.

In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage.

The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance.

Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway.

The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.